T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This open-label, single-center Phase Ib study will assess the safety and tolerability of
combining trastuzumab emtansine (T-DM1) with Lapatinib and Abraxane in patients with
metastatic HER2-positive breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Jenny C. Chang, MD
Collaborators:
The Methodist Hospital Research Institute The Methodist Hospital System